Fifty-three percent of Latinx and 49% of Black Medicare beneficiaries choose enrollment in Medicare Advantage; seeing average annual savings of $1,113 and $1,270, respectively, compared to Traditional Medicare.
New data released by Better Medicare Alliance, a research and advocacy group supporting Medicare Advantage, shows Medicare Advantage’s continued strength with diverse beneficiary populations.
The study, by ATI Advisory and based on 2018 Medicare Current Beneficiary Survey (MCBS) data finds 53% of Latinx Medicare beneficiaries choose enrollment in Medicare Advantage, as do 49% of Black beneficiaries.
Survey data shows Latinx beneficiaries spend $1,113 less when enrolled in Medicare Advantage compared with Traditional Fee-for-Service (FFS) Medicare, while Black beneficiaries see average savings of $1,270.
In addition, findings depict how Medicare Advantage beneficiaries of all races and ethnicities are more medically complex than those in Traditional FFS Medicare. Between 50-52% of Black, white, and Latinx Medicare Advantage beneficiaries report more than three chronic conditions, compared with 45-48% of Traditional FFS Medicare beneficiaries.
MCBS data also shows that Medicare Advantage beneficiaries are more likely to receive routine care than those enrolled in Traditional FFS Medicare. This includes higher rates of beneficiaries receiving mammograms, flu shots, blood pressure screenings, and cholesterol checks.
“Once again, the research demonstrates that Medicare Advantage is the preferred coverage choice for minority, lower-income, and medically complex beneficiaries – and is delivering meaningful cost savings and more preventive care as compared to Traditional Medicare,” Allyson Y. Schwartz, president and CEO of the Better Medicare Alliance, said. “With over 26.5 million beneficiaries enrolled in Medicare Advantage today, this report shows that minority beneficiaries are a driving force behind these enrollment gains; turning to Medicare Advantage to meet their health and social needs. When policymakers stand up for Medicare Advantage, they stand up for these seniors, too.”
Additional key findings from the study are below:
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More